![]() |
市場調査レポート
商品コード
1722104
治療用超音波の世界市場の評価:技術別、用途別、エンドユーザー別、地域別、機会、予測(2018年~2032年)Therapeutic Ultrasound Market Assessment, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
||||||
カスタマイズ可能
|
治療用超音波の世界市場の評価:技術別、用途別、エンドユーザー別、地域別、機会、予測(2018年~2032年) |
出版日: 2025年05月09日
発行: Market Xcel - Markets and Data
ページ情報: 英文 255 Pages
納期: 3~5営業日
|
世界の治療用超音波の市場規模は、2024年の14億1,652万米ドルから2032年に24億3,566万米ドルに達すると予測され、予測期間の2025年~2032年にCAGRで7.01%の成長が見込まれます。市場の成長は、幅広い用途、研究開発活動の活発化、製品のイノベーションへの注目の高まり、慢性疾患の有病率の上昇などによるものと考えられます。前立腺がんなどの疾患の患者数は大幅に増加しており、市場の需要を押し上げています。例えば、American Cancer Societyは、2025年に米国で約31万3,780人の前立腺がんの新規患者が報告されると推定しています。
非侵襲的治療への志向の高まりは、治療用超音波市場の拡大を促進している大きな要因です。患者も医療提供者も同様に、外科的介入の必要性を最小化し、合併症のリスクと回復時間を短縮する治療法を好んでいます。高密度焦点式超音波や体外衝撃波結石破砕術などの治療用超音波技術は、前立腺がん、子宮筋腫、筋骨格系の損傷、腎結石などの症状に対して安全で効果的な代替手段を提供することで、こうした選好に応えています。治療用超音波は、周囲に害を与えることなく特定の組織をターゲットにできるため、臨床的な魅力が高いです。このような利点に対する認識が医療従事者や患者の間で高まるにつれて、採用率は今後数年で大幅に上昇すると予測されます。
当レポートでは、世界の治療用超音波市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。
Global therapeutic ultrasound market is projected to witness a CAGR of 7.01% during the forecast period 2025-2032, growing from USD 1416.52 million in 2024 to USD 2435.66 million in 2032. The market's growth can be attributed to its wide range of applications, rising research and development activities, increasing emphasis on product innovation, and rising prevalence of chronic diseases. The number of cases of conditions such as prostate cancer are witnessing a significant increase, bolstering the market's demand. For instance, the American Cancer Society estimates that approximately 313,780 new cases of prostate cancer will be reported in the United States in 2025.
The growing inclination toward non-invasive treatments is a major factor driving the expansion of the therapeutic ultrasound market. Patients and healthcare providers alike prefer therapies that minimize the requirement for surgical intervention and reduce recovery time along with the risk of complications. Therapeutic ultrasound technologies, including high intensity focused ultrasound and extracorporeal shockwave lithotripsy, cater to these preferences by offering safe, effective alternatives for conditions such as prostate cancer, fibroids, musculoskeletal injuries, and kidney stones, among others. The ability of therapeutic ultrasound to target specific tissues without harming surrounding areas enhances its clinical appeal. As awareness of such benefits increases among healthcare professionals and patients, the adoption rate is expected to rise significantly in the coming years.
Increasing Investments Boost Market Growth
Rising investments in therapeutic ultrasound are expanding its clinical applications, boosting innovations, and improving their accessibility. Fundings from public and private sectors allows companies to boost their research and development efforts, resulting in the production of advanced systems and technologies that are both patient and clinician friendly. Improved flow of capital also supports regulatory approvals and large-scale clinical trials, accelerating the introduction of new products in different markets. Thus, various clinical stage medical device companies are focusing on procuring fundings. In April 2025, SecondWave Systems, Inc. raised USD 7 million in a series A funding round for developing a new treatment for inflammatory disorders that is ultrasound-based. This funding round builds on the prior funding received by the company from the Advanced Research Projects Agency for Health (ARPA-H) and the Defense Advanced Research Projects Agency (DARPA), which supported the prior research activities of the SecondWave MINI, a wearable, non-invasive therapeutic ultrasound device indicated for treating inflammatory diseases.
Technological Advancements Support Market Expansion
The increasing focus of leading medical device companies on innovation and new product launches is propelling the market's expansion. Innovations, such as high intensity focused ultrasound allow for non-invasive treatment of neurological disorders, uterine fibroids, and prostate cancer by enabling ablation of tumors, minimizing recovery time and reducing the requirement for surgery. Moreover, the integration of artificial intelligence is aiding in improving automated analysis, diagnostic accuracy, and image acquisition, making ultrasound more effective and accessible for medical professionals and augmenting their utilization in emergency settings and primary care.
Additionally, medical technology companies across the globe are also engaging in strategic partnerships and collaborations to introduce new technologies. In March 2025, TOOsonix A/S and Consultronix Capital Group formed a collaboration for introducing focused ultrasound skin therapy in Poland. Such collaborations allow companies to expand their presence across different regions and showcases the efficacy and versatility of ultrasound-based treatments, providing lucrative growth opportunities for the market.
High Intensity Focused Ultrasound Accounts for Significant Share of the Market
The segment's growth can be attributed to the high clinical versatility, safety, and efficacy of the technology across a wide range of medical applications. The non-invasive nature of the technique enhances patient convenience whereas the localized heat and ultrasound waves ensure the destruction of tumor cells, without damaging the healthy ones. This approach is particularly useful in treating oncological conditions as it fosters reduced pain, fewer complications, and faster recovery.
Thus, leading hospitals across the globe are focusing on introducing high intensity focused ultrasound in order to provide high-quality care to the patient population. For instance, in April 2025, Northampton General Hospital announced that they will be launching a new non-invasive treatment for prostate cancer. The high intensity focused ultrasound machine will allow the hospital to remove the unpleasant side effects associated with radiotherapy and surgeries. Other hospitals including Queen Elizabeth in King's Lynn, Norfolk are also planning on launching high intensity focused ultrasound for prostate cancer.
North America Holds Major Market Share
The region's dominance can be attributed to the strong presence of leading market players, high investments in the healthcare sector, and increasing prevalence of chronic diseases in countries such as Canada and the United States. Over 2 million new cases of cancer are expected to be diagnosed in the United States in 2025, as per the estimates of the American Cancer Society. Presence of robust training programs and increasing awareness among medical professionals about the various benefits associated with therapeutic ultrasound ensure their widespread utilization.
Additionally, the increasing preference for outpatient and minimally invasive therapies is also bolstering the market's growth and expansion in the region as therapeutic ultrasound lowers complication rates and reduces recovery time significantly. Moreover, supportive regulatory framework and reimbursement policies are further allowing clinics and hospitals across the region to adopt therapeutic ultrasound technologies.
Impact of the U.S. Tariff on Global Therapeutic Ultrasound Market
The tariffs could lead to potential disruptions in supply chains and increase the costs for imported equipment, boosting the prices for ultrasound devices for both international and domestic customers, impacting the growth of the market. On the other hand, these tariffs could incentivize companies to reshore their production within the United States or shift their manufacturing units to countries with lower tariffs, bringing changes to the landscape of the MedTech market.
The increased costs and uncertainty associated with the new tariffs could also potentially lead to a temporary slowdown in investment in therapeutic ultrasound companies, particularly in small manufacturers and startups. Moreover, other countries could retaliate with tariffs of their own, resulting in the addition of further complications, impacting the global supply chain of ultrasounds.
Key Players Landscape and Outlook
The key players of the market are focusing on receiving funding to explore other applications of focused ultrasound and introducing new technologies in the market. For instance, in November 2024, Acoustiic, Inc. received a funding agreement from the Focused Ultrasound Foundation (FUS) for adapting its WaveMatrix platform for exploring the different therapeutic applications of ultrasound in companion animals. The company partnered with the Veterinary Specialty Clinic for Anesthesia and Neurology (VSCAN) to explore the applications of focused ultrasound in care of companion animals with brain pathology. Such efforts are expected to stimulate the market's demand and attract further investments, providing lucrative growth opportunities for the market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.